Immix Biopharma Investor Presentation Deck
IMX-110 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety
in Soft Tissue Sarcoma (STS), and Encouraging Efficacy in Colorectal Cancer
100%
Relapsed/Refractory Soft Tissue
68%
Sarcoma
4.2
2.7
2.6
ht.
62%
58%
Disease Control at 2 months
IMX-110 7L
Johnson-Johnson
Yondelis
(trabectedin
2L
4.0
median PFS (months)
Doxorubicin 1L
3L
Eisai
Relapsed/Refractory Metastatic pMMR
Colorectal Cancer
Halaven
d
75%
NR (1%
ORR
reported)
2.0 2.0
Tumor Shrinkage median PFS
(months)
IMX-110 +
PD-19L
B
BAYER
K
Stivarga
fragorafenibles
4L
●
●
●
●●●
IMMIX
S BIOPHARMA
IMX-110 category leading
progression free survival (PFS)
in heavily pretreated patients
with zero drug-related SAES
IMX-110 100% Disease
Control at 2 months
(Doxorubicin 68% Yondelis
62% Halaven 58%)
IMX-110 treated STS patients
had 3-13 median prior lines of
therapies
IMX-110 + PD-1 treated r/r
colorectal cancer showed 75%
tumor shrinkage and mPFS not
reached (NR) at 2 months in
patients had 8 median prior
lines of therapies
Note: mPFS is Median Progression Free Survival. Dollar amounts are annual drug sales. Adapted from: Lorigan et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma
Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. doi: 10.1200/JCO.2006.09.7717. Judson et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4.
Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. Tawbi et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort,
single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. D'Angelo et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018 Mar;19(3):416-426. doi: 10.1016/S1470-
2045(18)30006-8. Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. D'Angelo et al. Pilot study of NKTR214 and nivolumab in patients with
sarcomas. Journal of Clinical Oncology 2019 37:15_suppl, 11010-11010. DOI: 10.1200/JCO.2019.37.15_suppl.11010. van der Graaf et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012
May 16. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. The global soft tissue sarcoma market is estimated to reach USD 6,465.7 million by 2030 from USD 2,943.3 million in 2019 according
to MedGadget. Per Stirvarga FDA approval label, Stivarga 1% Overall Response Rate (ORR) reported, tumor shrinkage not reported. pMMR: proficient mismatch repair
28View entire presentation